| __timestamp | Johnson & Johnson | Taro Pharmaceutical Industries Ltd. |
|---|---|---|
| Wednesday, January 1, 2014 | 21954000000 | 91733000 |
| Thursday, January 1, 2015 | 21203000000 | 87644000 |
| Friday, January 1, 2016 | 19945000000 | 92365000 |
| Sunday, January 1, 2017 | 21420000000 | 85656000 |
| Monday, January 1, 2018 | 22540000000 | 88196000 |
| Tuesday, January 1, 2019 | 22178000000 | 89971000 |
| Wednesday, January 1, 2020 | 22084000000 | 93413000 |
| Friday, January 1, 2021 | 20118000000 | 91355000 |
| Saturday, January 1, 2022 | 19046000000 | 113676000 |
| Sunday, January 1, 2023 | 20112000000 | 198366000 |
| Monday, January 1, 2024 | 21969000000 | 218935000 |
Unleashing the power of data
In the ever-evolving pharmaceutical industry, understanding the financial strategies of leading companies is crucial. Johnson & Johnson, a global healthcare leader, and Taro Pharmaceutical Industries Ltd., a niche player, offer a fascinating study in contrasts. From 2014 to 2023, Johnson & Johnson's Selling, General, and Administrative (SG&A) expenses have shown a steady pattern, peaking in 2018 with a 10% increase from 2016, before stabilizing around 2020. In contrast, Taro's SG&A expenses, though significantly smaller, have seen a remarkable rise, nearly doubling from 2014 to 2023. This divergence highlights Johnson & Johnson's consistent investment in maintaining its market dominance, while Taro's growth reflects its strategic expansion efforts. Notably, the data for 2024 is incomplete, suggesting ongoing developments in these companies' financial strategies. This analysis underscores the dynamic nature of the pharmaceutical sector and the varied paths companies take to achieve success.
Cost Management Insights: SG&A Expenses for Johnson & Johnson and AstraZeneca PLC
Operational Costs Compared: SG&A Analysis of Johnson & Johnson and Bristol-Myers Squibb Company
Selling, General, and Administrative Costs: Johnson & Johnson vs Verona Pharma plc
Johnson & Johnson or Merus N.V.: Who Manages SG&A Costs Better?
Comparing SG&A Expenses: Johnson & Johnson vs Bausch Health Companies Inc. Trends and Insights
Breaking Down SG&A Expenses: Johnson & Johnson vs Galapagos NV
Operational Costs Compared: SG&A Analysis of Dr. Reddy's Laboratories Limited and Taro Pharmaceutical Industries Ltd.
Blueprint Medicines Corporation vs Taro Pharmaceutical Industries Ltd.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Lantheus Holdings, Inc. or Taro Pharmaceutical Industries Ltd.
Selling, General, and Administrative Costs: Ultragenyx Pharmaceutical Inc. vs Taro Pharmaceutical Industries Ltd.
Comparing SG&A Expenses: Veracyte, Inc. vs Taro Pharmaceutical Industries Ltd. Trends and Insights
Who Optimizes SG&A Costs Better? Amphastar Pharmaceuticals, Inc. or Taro Pharmaceutical Industries Ltd.